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DOI 10.1016/j.immuni.2008.02.005Immune regulatory proteins such as
CIITA, NAIP, IPAF, NOD1, NOD2, NALP1,
and cryopyrin (also known as NALP3) are
members of a family characterized by the
presence of a NACHT nucleotide-binding
domain (NBD) and leucine-rich repeats
(LRRs). Members of this gene family en-
code a protein structure similar to the
NB-LRR subgroup of disease-resistance
genes in plants and are involved in the
sensing of pathogenic products and the
regulation of cell signaling and death. Cur-
rently, a variety of different names are
used to describe the products encoded
by the NBD and LRR containing gene fam-
ily, its subfamilies, and individual genes,
including CATERPILLER (CLR), NOD-LRR,
NACHT-LRR, NOD-like receptor, CARD,
NALP, NOD, PAN, and PYPAF. This lack
of consistency has led to a pressing need
to unify the nomenclature for this gene
family. Consequently, we propose a stan-
dardized nomenclature, NLR, which stands
for the nucleotide-binding domain and
leucine-rich repeat containing gene family.
The NLR family includes several sub-
families distinguishable by their N-termi-
nal effector domains. There are four rec-
ognizable NLR N-terminal domains:acidic transactivation domain, pyrin do-
main, caspase recruitment domain
(CARD), and baculoviral inhibitory repeat
(BIR)-like domains (see Table 1 for the hu-
man NLR genes). These N-terminal do-
mains have been used by several groups
to subdivide the NLR gene family, and
there are now multiple names for each
subfamily: the largest pyrin-containing
subfamily has been named PAN, NALP,
and PYPAF; members of the CARD-con-
taining subfamily have been named
CARDs or NODs; the BIR-containing sub-
family has been named NAIP or BIRC.
In consultation with over 100 scientists,
through a stepwise voting process orga-
nized by the Human Genome Organisa-
tion (HUGO) Gene Nomenclature Com-
mittee (HGNC) and conducted via email
and updated web pages, a new nomen-
clature system for human and mouse
NLR genes has been agreed upon (see
Table S1 available online for human and
mouse NLR genes). It was agreed that
the family name ‘‘nucleotide-binding do-
main and leucine-rich repeat containing’’
should be used to highlight these two evo-
lutionarily conserved domains and to re-
flect the similarity of the NLR family toImmuthe plant NB-LRR proteins. Furthermore,
the consensus of opinion was that a
subfamily-derived nomenclature system
based on the N-terminal effector domains
should be implemented. Consequently,
four subfamily designations have been
approved: NLRA, NLR family, acidic do-
main containing; NLRB, NLR family, BIR
domain containing; NLRC, NLR family,
CARD domain containing; NLRP, NLR
family, pyrin domain containing; NLRX,
NLR family with no strong homology to
the N-terminal domain of any other NLR
subfamily member (Table 1). Each mem-
ber within a subfamily is given a number,
e.g., NLRP1. Four members of the NLR
family, CIITA, NAIP, NOD1, and NOD2,
have not been renamed. These four genes
are associated with a large volume of liter-
ature, and it was agreed that renaming
these would cause confusion in the litera-
ture. However, each of these genes has
been given a subfamily alias to enable
electronic data-retrieval systems to link
these four genes to the NLR gene family.
Clearly related genes, such as NLRP10
and Naip3-6, that do not encode NBD
and/or LRR are included for complete-
ness and historic reasons.nity 28, March 2008 ª2008 Elsevier Inc. 285
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NLR Family HGNC-Approved Symbol Approved Name Other Names and Aliases Domain Organization Protein Sequence
NLRA CIITA class II, major
histocompatibility complex,
transactivator
NLRA; MHC2TA; C2TA (CARD)-AD-NACHT-NAD-
LRR
NP_000237
NLRB NAIP NLR family, apoptosis
inhibitory protein
NLRB1; BIRC1; CLR5.1 BIR3x-NACHT-LRR NP_004527
NLRC NOD1 nucleotide-binding
oligomerization domain
containing 1
NLRC1; CARD4; CLR7.1 CARD-NACHT-NAD-LRR NP_006083
NLRC NOD2 nucleotide-binding
oligomerization domain
containing 2
NLRC2; CARD15; CD;
BLAU; IBD1; PSORAS1;
CLR16.3
CARD2x-NACHT-NAD-LRR NP_071445
NLRC NLRC3 NLR family, CARD domain
containing 3
NOD3; CLR16.2 CARD-NACHT-NAD-LRR NP_849172
NLRC NLRC4 NLR family, CARD domain
containing 4
CARD12; CLAN; CLR2.1;
IPAF
CARD-NACHT-NAD-LRR NP_067032
NLRC NLRC5 NLR family, CARD domain
containing 5
NOD27; CLR16.1 CARD-NACHT-NAD-LRR NP_115582
NLRP NLRP1 NLR family, pyrin domain
containing 1
NALP1; DEFCAP; NAC;
CARD7; CLR17.1
PYD-NACHT-NAD-LRR-
FIIND-CARD
NP_127497
NLRP NLRP2 NLR family, pyrin domain
containing 2
NALP2; PYPAF2; NBS1;
PAN1; CLR19.9
PYD-NACHT-NAD-LRR NP_060322
NLRP NLRP3 NLR family, pyrin domain
containing 3
CIAS1; PYPAF1; Cryopyrin;
CLR1.1; NALP3
PYD-NACHT-NAD-LRR NP_004886
NLRP NLRP4 NLR family, pyrin domain
containing 4
NALP4; PYPAF4; PAN2;
RNH2; CLR19.5
PYD-NACHT-NAD-LRR NP_604393
NLRP NLRP5 NLR family, pyrin domain
containing 5
NALP5; PYPAF8; MATER;
PAN11; CLR19.8
PYD-NACHT-NAD-LRR NP_703148
NLRP NLRP6 NLR family, pyrin domain
containing 6
NALP6; PYPAF5; PAN3;
CLR11.4
PYD-NACHT-NAD-LRR NP_612202
NLRP NLRP7 NLR family, pyrin domain
containing 7
NALP7; PYPAF3; NOD12;
PAN7; CLR19.4
PYD-NACHT-NAD-LRR NP_996611
NLRP NLRP8 NLR family, pyrin domain
containing 8
NALP8; PAN4; NOD16;
CLR19.2
PYD-NACHT-NAD-LRR NP_789781
NLRP NLRP9 NLR family, pyrin domain
containing 9
NALP9; NOD6; PAN12;
CLR19.1
PYD-NACHT-NAD-LRR NP_789790
NLRP NLRP10 NLR family, pyrin domain
containing 10
NALP10; PAN5; NOD8;
PYNOD; CLR11.1
PYD-NACHT-NAD NP_789791
NLRP NLRP11 NLR family, pyrin domain
containing 11
NALP11; PYPAF6; NOD17;
PAN10; CLR19.6
PYD-NACHT-NAD-LRR NP_659444
NLRP NLRP12 NLR family, pyrin domain
containing 12
NALP12; PYPAF7;
Monarch1; RNO2; PAN6;
CLR19.3
PYD-NACHT-NAD-LRR NP_653288
NLRP NLRP13 NLR family, pyrin domain
containing 13
NALP13; NOD14; PAN13;
CLR19.7
PYD-NACHT-NAD-LRR NP_789780
NLRP NLRP14 NLR family, pyrin domain
containing 14
NALP14; NOD5; PAN8;
CLR11.2
PYD-NACHT-NAD-LRR NP_789792
NLRX NLRX1 NLR family member X1 NOD9; CLR11.3 X-NACHT-NAD-LRR NP_078894
The following abbreviations are used: AD, acidic activation domain CARD, caspase activating and recruitment domain; LRR, leucine-rich repeat;
NACHT, domain present in NAIP, CIITA, HET-E, and TP-1; BIR, baculovirus inhibitor of apoptosis repeat; PYD, pyrin domain; and NAD, NACHT-as-
sociated domain.To distinguish between human and
mouse NLR genes, the human genes are
written in upper case, whereas murine or-
thologs are distinguished from the human286 Immunity 28, March 2008 ª2008 Elseviegenes by the use of uppercase for the first
letter only, followed by lowercase (Table
S1). Although several human NLR genes
have multiple murine paralogs, some hu-r Inc.man NLR genes do not appear to have
any murine counterparts, reflecting the
dynamic evolutionary contraction and
expansion of this family.
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paper has been approved by the HGNC
and the Mouse Genomic Nomenclature
Committee. Concerted use of this unified
nomenclature will reduce confusion and
disparity and promote the transparency
of this important field. We urge all investi-
gators to adopt the approved nomencla-ture in future publications and presenta-
tions.
SUPPLEMENTAL DATA
A table of human and mouse NLR genes is avail-
able at http://www.immunity.com/cgi/content/full/
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